Latigo Biotherapeutics

The company's formation was spurred by the recognition of a significant lack of investment and quality licensable programs in the pain research sector. Seizing an opportunity, Westlake recruited a team of experienced drug hunters with deep expertise in pain and neuroscience, many of whom were available following Amgen's strategic exit from the neuroscience field. Bryan Moyer, who has over 20 years of R&D experience and previously led discovery programs at Amgen, co-founded Latigo and serves as the Senior Vice President of Discovery. The leadership team includes CEO Nima Farzan, Chief Medical Officer Dr. Neil Singla, and CFO Tim Lugo. The board is chaired by Timothy P. Walbert and includes notable figures like Dr. Beth Seidenberg and Dr. Nancy Stagliano.

Latigo's business model is centered on the discovery and clinical development of novel pain therapeutics. The company's scientific approach begins with identifying targets grounded in human biology and genetics. It employs a proprietary discovery engine that utilizes advanced techniques like artificial intelligence, machine learning, and structure-based design to create and optimize small molecule drug candidates for potency and selectivity. Latigo's primary focus is on the Nav1.8 sodium channel, a genetically validated target for pain that is specifically expressed in peripheral sensory neurons responsible for transmitting pain signals. By blocking this channel, their therapies aim to stop pain at its source before signals reach the central nervous system, thereby avoiding side effects like addiction and dizziness associated with opioids and other treatments.

The lead product candidate, LTG-001, is an oral, selective Nav1.8 inhibitor being developed for acute pain. It has completed a Phase 1 trial in healthy volunteers, demonstrating a favorable safety profile and rapid absorption. The FDA has granted Fast Track designation for LTG-001 for the treatment of acute pain, which will facilitate its development and regulatory review. The company's pipeline also includes LTG-305, another selective Nav1.8 inhibitor intended for chronic pain, which is also in Phase 1 trials with results anticipated in mid-2025. Beyond these, Latigo has additional small molecule programs in the discovery stage targeting novel, genetically identified pain pathways.